Human Milk Oligosaccharides for IBS Symptom Control and Microbiota Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with irritable bowel syndrome (IBS) face challenges with nutritional deficiencies and intestinal dysbiosis while on a low-FODMAP diet, and experience gastrointestinal symptoms when reintroducing FODMAPs.
Innovation Solution
The use of human milk oligosaccharides (HMOs) provides a source of oligosaccharides, increases bifidobacteria abundance, and allows for the reintroduction of FODMAPs without inducing gastrointestinal symptoms, thereby addressing nutritional deficiencies and symptom management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If a low-FODMAP diet is implemented to manage IBS symptoms, then gastrointestinal symptoms are reduced, but nutritional deficiencies and intestinal dysbiosis occur
Solution Approach 1:
The patent introduces human milk oligosaccharides (HMOs) as an intermediary substance that serves multiple functions: it provides necessary oligosaccharides for nutrition while being low-FODMAP friendly, acts as a prebiotic to promote beneficial bifidobacteria growth, and enables the safe reintroduction of FODMAPs without triggering gastrointestinal symptoms. This intermediary resolves the contradiction by simultaneously addressing nutritional needs and symptom management.
Solution Approach 2:
The patent changes the chemical composition parameters of the diet by incorporating HMOs with specific molecular structures (lacto-N-tetraose, lacto-N-neotetraose, and other human milk oligosaccharides). These parameter changes allow the diet to maintain low-FODMAP characteristics while providing essential nutritional components and beneficial microbial substrates, thereby resolving the contradiction between symptom control and nutritional adequacy.
2Quantity of substance
If FODMAPs are reintroduced to improve nutritional balance, then nutritional deficiencies are addressed, but gastrointestinal symptoms recur
Solution Approach 1:
HMOs serve as a bridge or intermediary that allows FODMAP reintroduction without triggering symptoms. The HMOs provide the necessary nutritional benefits and promote bifidobacteria growth while their unique molecular structure prevents them from being fermented by gut bacteria in a way that causes gas and bloating, thus enabling safe FODMAP reintroduction.
Solution Approach 2:
The patent replaces the traditional mechanical approach of gradual FODMAP reintroduction (which relies on patient tolerance and symptom monitoring) with a biochemical mechanism where HMOs specifically inhibit harmful bacterial fermentation while promoting beneficial bacteria. This substitution allows FODMAP reintroduction without the usual mechanical trial-and-error process.
3Object-affected harmful factors
If a low-FODMAP diet is followed long-term to control symptoms, then symptom management is improved, but intestinal microbiota composition changes unfavourably
Solution Approach 1:
HMOs act as a beneficial intermediary prebiotic that counteracts the negative effects of long-term low-FODMAP dieting. By specifically promoting bifidobacteria growth and maintaining diverse microbiota composition, HMOs preserve intestinal microbiota health while allowing continued symptom control through the low-FODMAP approach.
Solution Approach 2:
The patent employs a composite approach by combining HMOs with the low-FODMAP diet framework. This composite strategy integrates the symptom-control benefits of FODMAP restriction with the microbiota-preserving benefits of HMO supplementation, creating a unified dietary approach that addresses both contradictions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
HMOs effectively reduce gastrointestinal symptoms in IBS patients on a low-FODMAP diet, promote a healthy gut microbiota, and enable the safe reintroduction of FODMAPs, improving long-term nutritional balance and symptom control.
Implementation Method 1
These carbohydrates can be incompletely absorbed in the small intestine and pass into the large intestine where they are fermented by intestinal bacteria, leading to gas production and bloating.
Data Source
AI summary
A synthetic composition and method for use in providing a source of oligosaccharides to a human consuming a low-FODMAP diet, increasing the abundance of bifidobacteria in the colon of a human consuming a low-FODMAP diet, and/or reintroducing FODMAPs into the diet of a human consuming a low-FODMAP diet. The composition contains one or more human milk oligosaccharides.